Selling cannabidiol products in Canada: A framing analysis of advertising claims by online retailers.


Journal

BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562

Informations de publication

Date de publication:
01 07 2021
Historique:
received: 15 06 2020
accepted: 14 06 2021
entrez: 2 7 2021
pubmed: 3 7 2021
medline: 6 8 2021
Statut: epublish

Résumé

In Canada, the legalization of cannabis has enabled cannabidiol (CBD) to become a popular commercial product, increasingly used for medical or therapeutic purposes. There are currently over one thousand CBD products available globally, ranging from oil extracts to CBD-infused beverages. Despite increased usage and availability, the evidence supporting the medical efficacy of CBD is limited. Anecdotal evidence suggests CBD sellers represent their products for medical use through direct medical claims or advice, which in Canada, is not allowed under the Cannabis Act without Health Canada approval. However, it is not clear the extent of sellers making health claims or other strategies used to promote medical usage of CBD. The objective of this study is to determine how CBD sellers advertise their products online to consumers. The product descriptions of 2165 CBD products from 70 websites selling CBD products for human consumption in Canada were collected from January 14th CBD products are framed to prospective customer through three distinct frames: a specific cure or treatment (n = 1153), a natural health product (n = 872), and a product used in certain ways to achieve particular results (n = 1388). Product descriptions contained medical or therapeutic claims for 171 medical conditions and ailments, with 53.3% of products containing at least one claim. The most prevalent claims found in product descriptions were the ability to treat or manage pain (n = 824), anxiety (n = 609), and inflammation (n = 545). Claims were found for treating or managing serious and-life-threatening illnesses such as multiple sclerosis (n = 210), arthritis (n = 179), cancer (n = 169), Crohn's disease (n = 78), Parkinson's disease (n = 59), and human immunodeficiency virus (HIV) (n = 54). CBD most often came in oil/tincture/concentrate form (n = 755), followed by edibles (n = 428), and vaporizer pen/cartridge/liquid products (n = 290). The findings suggest CBD is represented as a medical option for numerous conditions and ailments. We recommend Health Canada to conduct a systematic audit of companies selling CBD for regulatory adherence.

Sections du résumé

BACKGROUND
In Canada, the legalization of cannabis has enabled cannabidiol (CBD) to become a popular commercial product, increasingly used for medical or therapeutic purposes. There are currently over one thousand CBD products available globally, ranging from oil extracts to CBD-infused beverages. Despite increased usage and availability, the evidence supporting the medical efficacy of CBD is limited. Anecdotal evidence suggests CBD sellers represent their products for medical use through direct medical claims or advice, which in Canada, is not allowed under the Cannabis Act without Health Canada approval. However, it is not clear the extent of sellers making health claims or other strategies used to promote medical usage of CBD. The objective of this study is to determine how CBD sellers advertise their products online to consumers.
METHODS
The product descriptions of 2165 CBD products from 70 websites selling CBD products for human consumption in Canada were collected from January 14th
RESULTS
CBD products are framed to prospective customer through three distinct frames: a specific cure or treatment (n = 1153), a natural health product (n = 872), and a product used in certain ways to achieve particular results (n = 1388). Product descriptions contained medical or therapeutic claims for 171 medical conditions and ailments, with 53.3% of products containing at least one claim. The most prevalent claims found in product descriptions were the ability to treat or manage pain (n = 824), anxiety (n = 609), and inflammation (n = 545). Claims were found for treating or managing serious and-life-threatening illnesses such as multiple sclerosis (n = 210), arthritis (n = 179), cancer (n = 169), Crohn's disease (n = 78), Parkinson's disease (n = 59), and human immunodeficiency virus (HIV) (n = 54). CBD most often came in oil/tincture/concentrate form (n = 755), followed by edibles (n = 428), and vaporizer pen/cartridge/liquid products (n = 290).
CONCLUSION
The findings suggest CBD is represented as a medical option for numerous conditions and ailments. We recommend Health Canada to conduct a systematic audit of companies selling CBD for regulatory adherence.

Identifiants

pubmed: 34210299
doi: 10.1186/s12889-021-11282-x
pii: 10.1186/s12889-021-11282-x
pmc: PMC8248754
doi:

Substances chimiques

Cannabidiol 19GBJ60SN5

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1285

Références

Am J Public Health. 2020 Oct;110(S3):S294-S299
pubmed: 33001729
JAMA Netw Open. 2020 Oct 1;3(10):e2020977
pubmed: 33057645
J Cannabis Res. 2020 Jan 2;2(1):2
pubmed: 33526132
Cannabis Cannabinoid Res. 2020 Nov 20;:
pubmed: 33998872
Soc Sci Med. 2012 Apr;74(8):1274-81
pubmed: 22386639
Cannabis Cannabinoid Res. 2020 Dec 15;5(4):274-278
pubmed: 33381640
J Diet Suppl. 2020;17(5):493-502
pubmed: 32543246
Neurol Sci. 2020 Nov;41(11):3085-3098
pubmed: 32556748
J Cannabis Res. 2021 May 6;3(1):13
pubmed: 33957993
Psychiatr Serv. 2021 Apr 1;72(4):429-436
pubmed: 33530732

Auteurs

Marco Antonio Zenone (MA)

Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, V5A 1S6, Canada. marco.zenone@lshtm.ac.uk.

Jeremy Snyder (J)

Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, V5A 1S6, Canada.

Valorie Crooks (V)

Department of Geography, Simon Fraser University, Burnaby, BC, V5A 1S6, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH